Celldex Therapeutics, Inc. (NASDAQ:CLDX): Insiders Are Dumping, Should You?

Is Celldex Therapeutics, Inc. (NASDAQ:CLDX) ready to raly soon? Money managers are selling. The number of bullish hedge fund bets stayed the same which is a slightly negative development in our experience

To the average investor, there are dozens of gauges shareholders can use to monitor their holdings. A couple of the most useful are hedge fund and insider trading activity. At Insider Monkey, our studies have shown that, historically, those who follow the best picks of the elite fund managers can outclass the S&P 500 by a healthy amount (see just how much).

Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Just as important, bullish insider trading activity is a second way to break down the marketplace. Obviously, there are lots of motivations for a corporate insider to sell shares of his or her company, but only one, very obvious reason why they would buy. Many empirical studies have demonstrated the market-beating potential of this tactic if you understand what to do (learn more here).

Now, we’re going to take a glance at the key action encompassing Celldex Therapeutics, Inc. (NASDAQ:CLDX).

How are hedge funds trading Celldex Therapeutics, Inc. (NASDAQ:CLDX)?

In preparation for this year, a total of 12 of the hedge funds we track were bullish in this stock, a change of 0% from one quarter earlier. With hedge funds’ positions undergoing their usual ebb and flow, there exists a select group of noteworthy hedge fund managers who were upping their holdings meaningfully.

According to our comprehensive database, Steven Cohen’s SAC Capital Advisors had the largest position in Celldex Therapeutics, Inc. (NASDAQ:CLDX), worth close to $18 million, comprising 0.1% of its total 13F portfolio. Sitting at the No. 2 spot is Arthur B Cohen and Joseph Healey of Healthcor Management LP, with a $14 million position; 0% of its 13F portfolio is allocated to the stock. Remaining hedgies that are bullish include Jean-Marie Eveillard’s First Eagle Investment Management, Donald Chiboucis’s Columbus Circle Investors and D. E. Shaw’s D E Shaw.

Judging by the fact that Celldex Therapeutics, Inc. (NASDAQ:CLDX) has experienced declining sentiment from the smart money, we can see that there is a sect of money managers who were dropping their positions entirely at the end of the year. Intriguingly, Wayne Holman’s Ridgeback Capital Management dumped the biggest position of all the hedgies we monitor, comprising about $18 million in stock., and Mike Vranos of Ellington was right behind this move, as the fund dropped about $0 million worth. These transactions are important to note, as total hedge fund interest stayed the same (this is a bearish signal in our experience).

How have insiders been trading Celldex Therapeutics, Inc. (NASDAQ:CLDX)?

Insider buying is most useful when the company in focus has seen transactions within the past half-year. Over the latest 180-day time frame, Celldex Therapeutics, Inc. (NASDAQ:CLDX) has experienced zero unique insiders buying, and zero insider sales (see the details of insider trades here).

With the results demonstrated by our time-tested strategies, everyday investors must always keep an eye on hedge fund and insider trading sentiment, and Celldex Therapeutics, Inc. (NASDAQ:CLDX) is an important part of this process.

Click here to learn more about Insider Monkey’s Hedge Fund Newsletter

Insider Monkey’s small-cap strategy returned 29.2% between September 2012 and February 2013 versus 8.7% for the S&P 500 index. Try it now by clicking the link above.

blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

10 Best States To Practice Medicine

The 10 Best States to Have a Business

The 12 Most Expensive Apple (AAPL) Apps in the Market

The 10 Richest Billionaires in the World

10 Biggest Kickstarter Failures

The 10 Best Places to Work At

The Top 10 of Google Inc (GOOGL)’s Most Expensive Acquisitions

13 Best Cities to Visit in South America

10 Most Expensive Works of Art of All Time

The 10 Richest Banks in the World

The 10 Best-Paying Jobs in America (2014)

7 Most Expensive Foods in the World

The World’s Top 10 Earning Authors

Five Wicked and Very Expensive Items (and Other “Stuff”) Sold on eBay

10 Biggest Celebrity Bankruptcies

The Top 10 Highest Paid CEOs in 2014

The 10 Most Expensive Real Estate Cities in America

10 Most Expensive States To Live In America

The 10 Best Airlines in the World

The 10 Best-Selling Cars in 2014

The 10 Best Industries to Invest In

The 10 Most Expensive States to Own a Car In

Top 10 Business Schools in US: 2014 Rankings

Top 20 Female Billionaires in 2014

6 Movies That You Should Watch to Better Understand The Cold War

Top 15 Best Paying Jobs for Women in 2014

Top 6 Things Rich People Do Differently Every Day

5 Retirement Mistakes To Avoid (and Einstein’s Famous Quote)

11 Smartest People in the World

6 Films About the Financial World You Need To Watch (While “The Wolf” is Not Around)

Warren Buffett and Billionaires Are Crazy About These 7 Stocks

The Top 10 States With Fastest Internet Speeds

10 Best Places to Visit in USA in August

Top 10 Cities to Visit Before You Die

Top 10 Genetically Modified Food In the US

15 Highest Grossing Movies Opening Weekend

5 Best Poker Books For Beginners

10 Strategies Hedge Funds Use to Make Huge Returns

Top 10 Fast Food Franchises to Buy

10 Best Places to Visit in Canada

Best Summer Jobs for Teachers

10 Youngest Hedge Fund Billionaires

Top 10 One Hit Wonders of the 90s

Fastest Growing Cities In America

Top 10 U.S. Cities for Freelancers

Top 9 Most Popular Free iPhone Apps

Top 10 Least Expensive Private Business Schools in the US

Top 15 Most Expensive Countries in the World – 2014

Top 6 Tax Scams and How to Protect Yourself

Top Businesses to Invest In

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!